Policy & Regulation
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
15 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Wednesday that its Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA (pembroliz...
Bruker expands infection diagnostics portfolio with DISQVER platform acquisition
15 July 2026 - Life science research and diagnostics solutions provider Bruker Corporation (Nasdaq:BRKR) announced on Wednesday that it has acquired the DISQVER clinical metagenomics platform from Nos...
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority re...
Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis
15 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage drug development company focused on immune and inflammatory diseases, announced on Tuesday the completion of patient enrolment in the Phase...
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-su...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...